The Synergistic Effects of rhArg with Bcl-2 Inhibitors or Metformin Co-Treatment in Multiple Cancer Cell Models
Cells · 2026
DOI: 10.3390/cells15020164 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Lai-Pan Sze und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, China. Hauptthemen laut MEDLINE: Metformin, Proto-Oncogene Proteins c-bcl-2, Arginase, Neoplasms. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PolyU Programme, Hong Kong Research Grant Council (RGC), General Research Fund, Lo Ka Chung Charitable Foundation.
Abstract (Originalsprache)
Background
Recombinant human arginase (rhArg) has been proven to exhibit an anticancer effect via arginine starvation. To further improve the efficacy of rhArg, we examined the feasibility of a combination strategy with Bcl-2 inhibitors (ABT263 and ABT199) or an antidiabetic drug (metformin) and investigated the mechanistic basis for these strategies.
Methods
The combination effects were evaluated in a panel of human cancer cell lines modeling pancreatic ductal carcinoma (PDAC), triple-negative breast cancer (TNBC), colorectal cancer (CRC) and glioblastoma (GBM). Western blot analysis was used to evaluate the expression of apoptotic and cell cycle markers. MTT assay was used to evaluate the combination efficacy. Flow cytometric assays were used to investigate the apoptotic and cell cycle effects.
Results
The combination of rhArg with sublethal doses of ABT263 significantly induced dose-dependent apoptosis, with elevated expression of apoptotic markers and a CI of 0.47 in U251. The combination inhibited CDK2 and cyclin A expression, indicating that the observed synergy also resulted from cell cycle arrest. We also found that rhArg + metformin was synergistic in a time-dependent manner. Compared to other amino acid depletion agents, rhArg + ABT263 was the most favorable combination pair.
Conclusions
The combination of rhArg and ABT263 enhanced apoptosis and cell cycle arrest, demonstrating a potential broad-spectrum antitumor strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, China.
- Lo Ka Chung Research Centre for Natural Anti-Cancer Drug Development, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, China.
- State Key Laboratory of Marine Food Processing and Safety Control, College of Food Science and Engineering, Ocean University of China, Qingdao 266404, China.
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
ORCID-Profile: Wing-Leung Wong, Leo Man-Yuen Lee, Yun-Chung Leung
Förderung
- PolyU Programme
- Hong Kong Research Grant Council (RGC), General Research Fund
- Lo Ka Chung Charitable Foundation
- State Key Laboratory of Chemical Biology and Drug Discovery
- Hong Kong Research Grants Council (RGC) General Research Fund
Zitieren
APA
Sze, L. P., Ho, V. M., Fung, W. K., Law, K. H., Tu, Y., So, Y. H., Chung, S. F., Wong, W. L., Liu, Z., Shum, A. S., Lee, L. M., & Leung, Y. C. (2026). The Synergistic Effects of rhArg with Bcl-2 Inhibitors or Metformin Co-Treatment in Multiple Cancer Cell Models. Cells. https://doi.org/10.3390/cells15020164
Vancouver
Sze LP, Ho VM, Fung WK, Law KH, Tu Y, So YH, et al. The Synergistic Effects of rhArg with Bcl-2 Inhibitors or Metformin Co-Treatment in Multiple Cancer Cell Models. Cells. 2026. doi:10.3390/cells15020164
BibTeX
@article{Sze2026,
author = {Sze, Lai-Pan and Ho, Vicky Mei-Ki and Fung, Wing-Ki and Law, Kin-Ho and Tu, Yifan and So, Yik-Hing and Chung, Sai-Fung and Wong, Wing-Leung and Liu, Zhen and Shum, Alisa Sau-Wun and Lee, Leo Man-Yuen and Leung, Yun-Chung},
title = {The Synergistic Effects of rhArg with Bcl-2 Inhibitors or Metformin Co-Treatment in Multiple Cancer Cell Models},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15020164}
}
EUVIMED